QSI vs. TXG, TRNS, EYPT, ALNT, LAB, CTKB, AEHR, QTRX, SENS, and MASS
Should you be buying Quantum-Si stock or one of its competitors? The main competitors of Quantum-Si include 10x Genomics (TXG), Transcat (TRNS), Eyepoint Pharmaceuticals (EYPT), Allient (ALNT), Standard BioTools (LAB), Cytek Biosciences (CTKB), Aehr Test Systems (AEHR), Quanterix (QTRX), Senseonics (SENS), and 908 Devices (MASS). These companies are all part of the "measuring and control equipment" industry.
Quantum-Si vs. Its Competitors
10x Genomics (NASDAQ:TXG) and Quantum-Si (NASDAQ:QSI) are both small-cap measuring and control equipment companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, valuation, institutional ownership, dividends, risk, media sentiment, analyst recommendations and earnings.
84.7% of 10x Genomics shares are held by institutional investors. Comparatively, 39.9% of Quantum-Si shares are held by institutional investors. 10.0% of 10x Genomics shares are held by insiders. Comparatively, 23.0% of Quantum-Si shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
In the previous week, Quantum-Si had 3 more articles in the media than 10x Genomics. MarketBeat recorded 6 mentions for Quantum-Si and 3 mentions for 10x Genomics. 10x Genomics' average media sentiment score of 1.39 beat Quantum-Si's score of 0.32 indicating that 10x Genomics is being referred to more favorably in the media.
10x Genomics currently has a consensus target price of $14.96, indicating a potential upside of 15.00%. Quantum-Si has a consensus target price of $3.48, indicating a potential upside of 67.07%. Given Quantum-Si's stronger consensus rating and higher probable upside, analysts clearly believe Quantum-Si is more favorable than 10x Genomics.
10x Genomics has a net margin of -25.14% compared to Quantum-Si's net margin of -2,925.41%. 10x Genomics' return on equity of -23.22% beat Quantum-Si's return on equity.
10x Genomics has a beta of 2.03, indicating that its share price is 103% more volatile than the S&P 500. Comparatively, Quantum-Si has a beta of 2.89, indicating that its share price is 189% more volatile than the S&P 500.
Quantum-Si has lower revenue, but higher earnings than 10x Genomics. 10x Genomics is trading at a lower price-to-earnings ratio than Quantum-Si, indicating that it is currently the more affordable of the two stocks.
Summary
Quantum-Si beats 10x Genomics on 9 of the 16 factors compared between the two stocks.
Get Quantum-Si News Delivered to You Automatically
Sign up to receive the latest news and ratings for QSI and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding QSI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Quantum-Si Competitors List
Related Companies and Tools
This page (NASDAQ:QSI) was last updated on 7/6/2025 by MarketBeat.com Staff
Free QSI Stock Alerts